事前審査・届出
カナダ ／ Health Canada／PAAB
市販後の医薬品広告の事前審査は独立・自主規制・任意の制度として運営され、医療従事者向けはPAAB、消費者向けの一般用医薬品および天然健康製品はAdvertising Standards CanadaおよびMIJOが審査する。
Preclearance of advertising for marketed health products is administered through an independent, self-regulatory and voluntary system, with PAAB reviewing material directed to health professionals and Advertising Standards Canada and MIJO reviewing non-prescription drug and natural health product material directed to consumers.
注記
The page as fetched contains no exception making preclearance mandatory for any product class; a claim seen in secondary sources that preclearance is mandatory for opioids was NOT confirmed on this page and is therefore not stated here.
The page as fetched contains no exception making preclearance mandatory for any product class; a claim seen in secondary sources that preclearance is mandatory for opioids was NOT confirmed on this page and is therefore not stated here.
補足 ── 当方未検証
下記は 提供文書『世界の医薬品広告規制、承認内外の境界を読み解く』(2026-09-23) に記載のある内容です。出典の記載はありますが、当方で原典に当たって確かめていません。上の検証済みの記述とは区別してお読みください。
- Health Canada の2023年7月31日ガイダンスは『広告か否か』を6要因で判定し、営業・マーケティング担当者が off-label 照会に回答すればそれ自体が広告該当性の要因になるとする。